Another example is a trifunctional NK-cell engager that targets NKp46 and CD16 on the NK cells and a tumor antigen on the tumor cell, showing better efficacy than standard monoclonal antibodies, such as cetuximab or rituximab [116]. This evidence concerns the gene NCR1 and neoplasm.